FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to producing immunogenic fused protein consisting of N-terminal sections of surface proteins Streptococcus of a group B; it can be used in medicine.
EFFECT: produced fused protein consisting of N-terminal sections of Alp1 protein and Alp2 protein can be used in the composition of a vaccine capable of causing protective immunity against Streptococcus of a group B containing surface proteins Alp1 and Alp2.
16 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | 2015 |
|
RU2735101C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| NEW HAEMOPHILUS PARASUIS VACCINE | 2020 |
|
RU2822516C1 |
| PNEUMOCOCCAL VACCINE COMBINING SELECTED ALPHA HELICAL DOMAINS AND PROLINE-RICH DOMAINS OF PNEUMOCOCCAL SURFACE PROTEIN A | 2017 |
|
RU2794625C2 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| METHOD FOR CREATING LIVE STRAIN OF ENTEROCOCCUS L3-SARS BASED ON BIOLOGICALLY ACTIVE STRAIN OF E. FAECIUM L3 | 2021 |
|
RU2782529C1 |
| PNEUMOCOCCAL SURFACE PROTEINS | 2020 |
|
RU2818278C2 |
| MODIFIED PROTEIN BINDING FACTOR H | 2017 |
|
RU2773464C1 |
| TREATMENT AND PREVENTION OF ALLERGY TO HOUSE DUST MITES | 2019 |
|
RU2815386C2 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
